Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease.
1 The chronotropic and inotropic properties of U.K. 14275, a phosphodiesterase inhibitor were assessed in patients with coronary heart disease. 2 Left ventricular function was assessed in eight patients with acute myocardial infarction using the non-invasive measurement of systolic time intervals. 3 Twelve patients with angina pectoris were studied during diagnostic coronary arteriography. Left ventricular function was assessed using a high fidelity catheter tipped transducer in the left ventricle. 4 In both groups of patients U.K. 14275 infused intravenously in doses of 32, 64, 128 and 256 microgram kg-1 bodyweight min-1 enhanced the contractile state of the left ventricle without altering the heart rate.
D003327:Coronary Disease / Q000503:physiopathology* / Q000601:surgery; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D009203:Myocardial Infarction / Q000503:physiopathology; D010726:Phosphodiesterase Inhibitors; D010880:Piperidines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D011799:Quinazolines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*
D010726:Phosphodiesterase Inhibitors; D010880:Piperidines; D011799:Quinazolines